NCT04234048 2025-09-22Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaSciTech Development, Inc.Phase 1 Recruiting46 enrolled
NCT01187810 2022-03-31Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHLSouth Plains Oncology ConsortiumPhase 1 Terminated3 enrolled
NCT02495415 2019-07-23Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell LymphomasCerRx, Inc.Phase 2 Unknown140 enrolled
NCT00104923 2017-07-19Fenretinide in Treating Patients With Refractory or Relapsed Hematologic CancerCalifornia Cancer ConsortiumPhase 1 Completed29 enrolled
NCT00288067 2014-10-06Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1/2 Terminated32 enrolled 7 charts